FIGURE 3.
The role of CA19.9 monitoring on treatment management. ((a)–(b)) Presence of relative indications for surgery other than (excl.) CA19.9 elevation (RI), absolute indications for surgery (AI) 9 and elevated CA19.9 values over time for individuals who develop high‐grade dysplasia (HGD) or pancreatic cancer (PC; (a)) and other pathology‐proven lesions (b); (c) Overview of participants with two or more available CA19.9 values who did not undergo surgery, showing the high frequency of elevated values. IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; NET, neuro‐endocrine tumor; PA‐proven, pathology proven; SPN, solid pseudopapillary neoplasm.